Literature DB >> 24726906

Proton pump inhibitors reduce the size and acidity of the acid pocket in the stomach.

Wout O Rohof1, Roelof J Bennink2, Guy E Boeckxstaens3.   

Abstract

BACKGROUND & AIMS: The gastric acid pocket is believed to be the reservoir from which acid reflux events originate. Little is known about how changes in position, size, and acidity of the acid pocket contribute to the therapeutic effect of proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD).
METHODS: Thirty-six patients with GERD (18 not taking PPIs, 18 taking PPIs; 19 men; age, 55 ± 2.1 y) were analyzed by concurrent high-resolution manometry and pH-impedance monitoring after a standardized meal. The acid pocket was visualized using scintigraphy after intravenous administration of (99m)technetium-pertechnetate. The size of the acid pocket was measured and its position was determined, relative to the diaphragm, using radionuclide markers on a high-resolution manometry catheter. At the end of the study, the acid pocket was aspirated, and its pH level was measured.
RESULTS: The number of reflux episodes was comparable between patients on and off PPIs, but the number of acid reflux episodes was reduced significantly in patients on PPIs. In patients on PPIs, the acid pocket was smaller and more frequently located below the diaphragm. The mean pH of the acid pocket was significantly lower in patients not taking PPIs (n = 6) than in those who were (n = 16) (0.9; range, 0.7-1.2 vs 4.0; range, 1.6-5.9; P < .001). The pH of acid pockets correlated significantly with the lowest pH values measured for refluxate (r = 0.72; P < .01).
CONCLUSIONS: Based on analyses of acid pockets in patients with GERD, the acid pocket appears to be a reservoir from which reflux occurs when patients are receiving PPIs. PPIs might affect the size, acidity, or position of the acid pocket, which contributes to the efficacy in patients with GERD.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug; Esophagus; Lower Esophageal Sphincter Relaxations; Stomach

Mesh:

Substances:

Year:  2014        PMID: 24726906     DOI: 10.1016/j.cgh.2014.04.003

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  12 in total

Review 1.  Medical Therapy of Gastroesophageal Reflux Disease Beyond Proton Pump Inhibitors: Where Are We Heading?

Authors:  Herbert Koop
Journal:  Visc Med       Date:  2018-03-29

2.  Postprandial proximal gastric acid pocket and its association with gastroesophageal acid reflux in patients with short-segment Barrett's esophagus.

Authors:  Yuan-Yuan Nian; Xian-Mei Meng; Jing Wu; Fu-Chu Jing; Xue-Qin Wang; Tong Dang; Jun Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2020-07       Impact factor: 3.066

3.  Hepatocyte Transplantation.

Authors:  Ira J Fox
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

4.  Management of the Acid Pocket.

Authors:  Peter J Kahrilas
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

Review 5.  Mechanisms of Barrett's oesophagus (clinical): LOS dysfunction, hiatal hernia, peristaltic defects.

Authors:  Sabine Roman; Peter J Kahrilas
Journal:  Best Pract Res Clin Gastroenterol       Date:  2014-11-12       Impact factor: 3.043

6.  Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.

Authors:  A De Ruigh; S Roman; J Chen; J E Pandolfino; P J Kahrilas
Journal:  Aliment Pharmacol Ther       Date:  2014-07-10       Impact factor: 8.171

7.  Proton pump inhibitors reduce the size and acidity of the gastric Acid pocket.

Authors:  Yun Ju Jo
Journal:  J Neurogastroenterol Motil       Date:  2015-01-31       Impact factor: 4.924

8.  Volume, distribution and acidity of gastric secretion on and off proton pump inhibitor treatment: a randomized double-blind controlled study in patients with gastro-esophageal reflux disease (GERD) and healthy subjects.

Authors:  Andreas Steingoetter; Matthias Sauter; Jelena Curcic; Dian Liu; Dieter Menne; Michael Fried; Mark Fox; Werner Schwizer
Journal:  BMC Gastroenterol       Date:  2015-09-02       Impact factor: 3.067

9.  Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.

Authors:  J Sun; C Yang; H Zhao; P Zheng; J Wilkinson; B Ng; Y Yuan
Journal:  Aliment Pharmacol Ther       Date:  2015-07-31       Impact factor: 8.171

10.  Evaluations of Gastric Acid Pocket Using Novel Vertical 8-Channel pH Monitoring System and Effects of Acid Secretion Inhibitors.

Authors:  Shohei Sumi; Norihisa Ishimura; Hironobu Mikami; Eiko Okimoto; Yuji Tamagawa; Tsuyoshi Mishiro; Yoshikazu Kinoshita; Shunji Ishihara
Journal:  J Neurogastroenterol Motil       Date:  2021-07-30       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.